Posted by Michael Wonder on 26 Oct 2024
FDA grants rare paediatric disease designation to Omeros’ MASP-3 inhibitor zaltenibart for treatment of C3 glomerulopathy
24 October 2024 - Phase 3 studies on the horizon in both PNH and C3G.
Omeros Corporation today announced that zaltenibart has received rare paediatric disease designation from the US FDA for the treatment of complement 3 glomerulopathy (C3G), an ultra rare, progressive renal disorder primarily afflicting children and young adults.
